High-purity reagents, market intelligence, and assay solutions for Integrated Stress Response (ISR) and transcription factor drug discovery. ATF4 (Activating Transcription Factor 4, CREB2) is a master bZIP transcription factor regulating the Unfolded Protein Response (UPR), amino acid sensing, and cellular stress adaptation. Its intracellular localization and bZIP family homology necessitate sophisticated in vitro assays for therapeutic development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATF4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | ATF4 Recombinant Protein (Full-Length & bZIP Domain 281-351); >95% purity, <0.1 EU/μg endotoxin, sequence verified (E. coli or HEK293 expressed). | View ATF4 Products |
| Antigen (Mutant Panel) | Dominant Negative (bZIP 281-351), Basic Region Mutant (R285A/R286A), Phospho-Mutants (S245A, S245D) – for mechanism and specificity controls. Theoretical MW confirmed. | View ATF4 Products |
| Gene Delivery | ATF4 ORF Lentivirus Particles (CMV promoter, Puro selection); full-length ORF for stable cell lines and reporter assays. | View ATF4 Products |
| Detection Ab | Anti-ATF4 Rabbit mAb (Clone TF4-1); Sequence Verified, for WB, IP, ChIP. | View ATF4 Products |
| Validator | ATF4 siRNA Set (3 unique targets, pooled); for knockdown verification and specificity controls. | View ATF4 Products |
| Heterodimer Partner | DDIT3 (CHOP) Recombinant Protein (bZIP domain); for EMSA/SPR heterodimerization studies. | View DDIT3 Products |
| Paralog Control | ATF3 Recombinant Protein; for subfamily specificity counter-screening. | View ATF3 Products |
| Upstream Kinase | EIF2AK3 (PERK) Recombinant Protein; for upstream pathway reconstitution and inhibitor profiling. | View EIF2AK3 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage |
|---|---|
| bZIP Family Selectivity & Off-Target Toxicity | High-purity recombinant ATF4, C/EBPα, C/EBPβ, ATF2, and ATF3 bZIP domains for orthogonal counter-screens. |
| DNA-Binding Specificity Validation | Sequence Verified Wild-Type vs. Basic Region Mutant (R285A/R286A) pair for negative control in EMSA/SPR. |
| Phosphorylation State Ambiguity | Phospho-Mimetic (S245D) and Non-Phosphorylatable (S245A) mutants for defined mechanistic studies. |
| PROTAC Ternary Complex Validation | High-purity, endotoxin-controlled full-length ATF4 protein for SPR/TR-FRET binding assays. |
| Cellular Reporter Assay for Transcriptional Activity | ATF4 ORF Lentivirus for stable reporter cell line generation; co-validated with ATF4 siRNA as specificity control. |
| Protein Aggregation during Purification | HEK293 expressed (mammalian folding) or E. coli expressed with refolding optimization; endotoxin <0.1 EU/μg. |
Live ATF4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ATF4 has shifted from broad Integrated Stress Response (ISR) modulation (e.g., PERK inhibitors, eIF2B activators) to precise, direct transcription factor interference. First-generation upstream kinase inhibitors encountered dose-limiting toxicities, prompting R&D toward ATF4 translational blockers, bZIP DNA-binding disruptors, heterodimer (ATF4-CHOP) interface inhibitors, and targeted protein degradation (PROTACs/molecular glues). The next wave emphasizes combination strategies with proteasome inhibitors in multiple myeloma, amino acid deprivation therapies in solid tumors, and neuroprotection in ALS/Alzheimer's disease. Accurate biochemical assays using high-purity recombinant domains are critical for distinguishing true PPI inhibitors from DNA-binding blockers and for assessing ternary complex formation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI/Transcriptional Inhibitor) | Calico, Novartis, Astellas, Academic Consortia | Solid Tumors, Neurodegeneration | bZIP Selectivity Panel & Cell-Based Reporter Assays (Need purified ATF4, CHOP, C/EBP proteins) |
| PROTAC / Molecular Glue | Emerging Biotech, Academic Spin-offs | Multiple Myeloma, Solid Tumors (Pancreatic, Breast) | Ternary Complex Validation & Cellular Degradation Assays (Need full-length ATF4, endotoxin-free; Lentivirus + siRNA) |
| Peptide / Peptidomimetic | Preclinical Startups | Metabolic Disorders | AlphaScreen/FP (Need high purity bZIP domain, sequence verified) |
| Gene Therapy (ASO/RNAi) | Preclinical Pipelines | Metabolic Disorders, Oncology | Target Knockdown Verification (Need validated siRNA and antibodies) |
| Indirect ISR Modulators (eIF2B activators, PERK inhibitors) | Denali Therapeutics, Calico/AbbVie | ALS, Alzheimer's Disease | Selectivity Assay (Need high-purity upstream kinases and ATF4 reporter lines) |
Related Targets for Cross-Selling
- DDIT3 (CHOP): Key heterodimeric partner; essential for ATF4:CHOP interface inhibitor studies. Co-purchase of both recombinant proteins recommended for Co-IP and SPR dimerization assays.
- EIF2AK3 (PERK): Upstream kinase regulating ATF4 translational induction; critical for combination and resistance-bypass studies.
- SLC7A11 (xCT): Downstream target of ATF4 mediating ferroptosis resistance; bundle with ATF4 tools for metabolic stress assays.